What Else EBO2 (EBOO) Clinics Sell: HBOT, Chelation, IV Drips, Stem Cells

Most places that sell EBO2 (also called EBOO) sell several other things too, and the second item is often proposed in the same conversation as the first. This guide counts what those other services actually are across every clinic in our directory, then sets out, for each of the common ones, what the service is, what the FDA has approved or cleared it for, what Medicare will and will not pay for, and the questions worth asking when it arrives bundled with an EBO2 session.

What the directory shows

Our directory records the services each clinic lists on its own website. As of September 28, 2026, across 177 listed US clinics:

Two further counts describe the shape of this. Sixty-eight of the 177 listings record EBO2 with no other service, so a single-service clinic is common. At the other end, 52 listings record three or more other services, 14 record five or more, and 103 of the 177 list at least one of hyperbaric oxygen, chelation, IV nutrient therapy, PRP, peptides, or NAD+. Twenty-one list another ozone method, usually major autohemotherapy or 10-pass, which we compare in our guide to EBO2 against 10-pass ozone.

A service is recorded when the clinic’s own site lists it, so these are floors rather than ceilings: a clinic may offer more than its website shows. The numbers are counts of listings, not of revenue, visits, or how hard any service is sold.

Hyperbaric oxygen therapy

What it is: breathing oxygen at a concentration far above air inside a chamber pressurized above normal atmospheric pressure.

Its status: hyperbaric chambers are regulated as devices rather than drugs. The FDA states that “HBOT devices are Class II medical devices and are cleared by the FDA through the 510(k) process”, and that cleared devices can be identified by searching product code CBF in the agency’s 510(k) database [2]. Clearance is a finding of substantial equivalence to a device already on the market, and the FDA’s own regulation says that representing it as official approval “is misleading and constitutes misbranding” [9]; the agency’s consumer page gives dialysis equipment as its example of this Class II route [10].

What it is paid for: Medicare’s national coverage determination on hyperbaric oxygen lists the conditions it will reimburse, including acute carbon monoxide intoxication, decompression illness, gas embolism, gas gangrene, acute traumatic peripheral ischemia, crush injuries, progressive necrotizing infections, acute peripheral arterial insufficiency, preparation of compromised skin grafts, chronic refractory osteomyelitis, osteoradionecrosis, soft tissue radionecrosis, cyanide poisoning, actinomycosis, and diabetic lower-extremity wounds in patients meeting three stated criteria [1]. It then states: “All other indications not specified under §270.4(A) are not covered under the Medicare program” [1]. The same document lists conditions it will not pay for at all, among them cutaneous, decubitus, and stasis ulcers, chronic peripheral vascular insufficiency, senility, myocardial infarction, and cerebral vascular insufficiency [1].

One safety note from the FDA belongs here because it concerns the setting rather than the biology: the agency wrote to health care providers in 2025 that it “is aware of recent reports of fires that occurred with HBOT devices that resulted in serious injuries and deaths”, that the root cause was not then known, and that providers should follow manufacturer instructions on grounding, clothing, training, and monitoring [2].

Ask: which of those listed conditions am I being treated for? If none, what is the chamber being used for, how many sessions, at what total cost, and what evidence is being offered? Who is trained to run it, and what are the fire-safety rules in this facility?

Chelation

What it is: giving a chemical, usually EDTA, that binds metals so they can be excreted. Its established use is metal poisoning.

Its status: the FDA states that “All FDA-approved chelation therapy products require a prescription because they can only be used safely under the supervision of a healthcare practitioner”, and, asked whether any over-the-counter chelation product is approved, answers: “No. FDA has never approved any chelation product for OTC use for any health condition” [4]. The agency says it is concerned about serious side effects “such as dehydration, kidney failure, and death”, and about people delaying necessary care while relying on unapproved products, which are commonly marketed to patients with serious conditions and for detoxification [4]. It also notes that companies selling these products often sell home metal-screening tests, which it says it has not cleared [4].

What it is paid for: Medicare’s determination is blunt. It states that EDTA chelation therapy for atherosclerosis “is controversial”, that “its clinical effectiveness has never been established by well designed, controlled clinical trials”, that it “is considered experimental”, and that “EDTA chelation therapy for the treatment or prevention of atherosclerosis is not covered” [3]. The same determination tells claims processors to deny claims that relabel the same therapy under other names [3].

Ask: is this a prescription product given under supervision, and for which diagnosis? What test established the metal burden being treated, who ran it, and is that test FDA-cleared? What is the monitoring plan for kidney function and electrolytes? If this is being sold for heart disease or for a general toxin burden, what evidence supports that use?

IV nutrient therapy and drips

What it is: vitamins, minerals, amino acids, or other substances infused into a vein, often sold under names such as Myers cocktail, immunity drip, or hangover drip, and increasingly bundled with EBO2 as a before-or-after add-on.

Its status: the ingredients vary, and so does the regulation. Where a clinic uses a compounded preparation rather than an FDA-approved product, the agency’s position is explicit: “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed”, and compounded drugs “should only be used in patients whose medical needs cannot be met by an FDA-approved drug” [6]. Quality standards differ by setting: products made in registered outsourcing facilities are subject to current good manufacturing practice requirements, while those compounded by a pharmacist in a state-licensed pharmacy or by a physician under section 503A are not [6].

On the claims, the FTC brought what it called its first action against a marketer of intravenous cocktail therapy in 2018, charging that the company advertised its drips as treatments for serious diseases including cancer, congestive heart failure, multiple sclerosis, diabetes, and neurodegenerative disorders, and as more effective and better tolerated than conventional therapy. The settling order bars those claims unless supported by competent and reliable scientific evidence, and the Commission’s chairman said at the time: “Health claims must be supported by competent and reliable scientific evidence” [5]. The release notes the drips cost $100 or more per session [5].

For anyone who competes under an anti-doping code, a bundled drip raises a separate question that has nothing to do with what is in it. USADA’s note on infusions says that IV infusions or injections “are prohibited both in- and out-of-competition if the amount is over 100 mL within a 12-hour period”, even when the substance itself is permitted, with exceptions for hospital and emergency treatment, surgery, and diagnostic procedures [12]. Our guide for athletes sets out that rule and the blood-manipulation rules as anti-doping agencies word them.

Ask: exactly what is in the bag, at what dose, and is each component an FDA-approved product for this use or a compounded preparation? If compounded, by whom, in a 503A pharmacy or a 503B outsourcing facility? What is the total volume and over what period? What is this expected to do that an oral equivalent would not?

Stem cell, exosome, PRP, peptide, and NAD+ services

These are grouped here because clinics group them, usually under a heading such as regenerative or anti-aging. Their regulatory positions are not the same, and the differences are the useful part.

For stem cells and exosomes the FDA’s consumer alert is unusually direct. It states that “generally, all stem cell products require FDA approval”, that “Currently, the only stem cell products that are FDA-approved for use in the United States consist of blood-forming stem cells (also known as hematopoietic progenitor cells) that are derived from umbilical cord blood”, approved for disorders of blood production and not for other uses, and that “There are currently no FDA-approved exosome products” [7]. The alert then lists what has not been approved, including treatment of “any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain”, any neurological disorder, any cardiovascular or lung disease, and “autism, macular degeneration, blindness, chronic pain, or fatigue” [7]. It covers products described as coming from adipose tissue, umbilical cord blood, Wharton’s jelly, or amniotic fluid [7].

Enforcement has followed the claims. In 2018 the FTC settled with a physician and two companies over advertising that amniotic stem cell therapy could treat Parkinson’s disease, autism, macular degeneration, cerebral palsy, multiple sclerosis, and heart attacks; the order bars such claims without competent and reliable scientific evidence, imposes a partially suspended judgment of $3.31 million, and required the defendants to notify current and former patients within 30 days [8].

Peptides and NAD+ are usually drug products rather than devices or biologics, and the question that decides their status is whether the specific product is FDA-approved for the use proposed or is a compounded preparation, which brings the compounding position above into play [6]. We did not find an FDA consumer statement addressing platelet-rich plasma specifically, so we make no claim about its status here; it is listed in the table above because clinics list it.

Ask: which product is this exactly, what is it approved for, and in whom? If the answer is that it is not approved for this use, what is the basis for offering it? Is there a clinical trial I could join instead, and would having this affect my eligibility for one?

Why a bundle is harder to judge than a single treatment

• The costs stack. Each service is a separate charge, often sold as a package before the first session. The price block below shows what clinics publish for EBO2 alone; a bundle sits on top of that, and our session cost planner and price check tool take a quoted figure apart.
• Attribution disappears. If three things are given in the same week, no one can say which produced an improvement, and, more importantly, which produced a side effect.
• Contraindications multiply. Each service has its own cautions, and the combination has not been studied. Our contraindications guide and our record of ozone adverse events by route cover the EBO2 side of that.
• The sales logic runs one way. Bundles are built to raise the value of a visit. That does not make them wrong, but it does mean the reason a second service was proposed may not be clinical, and asking which problem it addresses is a fair question.
• A cleared or registered device in the bundle does not validate the bundle. Ozone therapy is not FDA-approved for any medical use, and the federal rule states that ozone “is a toxic gas with no known useful medical application in specific, adjunctive, or preventive therapy” [11]; separately, a 510(k) clearance for a machine is not approval of a treatment [9][10].

A checklist for a bundle conversation

• Ask for an itemized price list, in writing, with each service priced separately and the package price shown next to the sum of its parts.
• Ask which condition or finding each component addresses, and what measurement would show it had worked. The claims block below shows which conditions clinics most often attach to EBO2 itself, a useful comparison when a bundle is proposed for the same conditions.
• Ask what is FDA-approved or cleared, for what, and request the product name so you can check it yourself.
• Ask what happens if you stop after the first session: is the package refundable, transferable, or lost?
• Ask who is physically present during each service, what their licence is, and what the emergency plan is.
• Ask whether any component affects your eligibility for a clinical trial, or, if you compete, your anti-doping status.
• Compare what the clinic tells you before you book against what clinics generally publish, in the transparency block below and in our clinic directory.

What we could not verify

• Whether a clinic offers a service it does not list, or no longer offers one it does. Our counts come from listings recorded from clinic websites and read on September 28, 2026, and the directory shows the date for each.
• What any clinic charges for a bundle. Our price data covers published single-session EBO2 prices and packages, and few clinics publish prices for the other services at all.
• The regulatory status of platelet-rich plasma in the United States. We did not find an FDA consumer statement addressing it, and we make no claim about it here.
• Whether the services listed are given in the same visit, in the same course, or separately. The listing records what is offered, not how it is sequenced.
• Whether bundled services interact with EBO2. We found no study of any such combination, which means no evidence of harm and no evidence of safety.
• How clinics describe these services, in their own words, beyond what we recorded for the EBO2 service itself. Our research pass read EBO2 pages, not every service page on every site.

How this guide was made

This guide draws on 12 primary sources: two Medicare national coverage determinations, five FDA publications and regulations, two FTC enforcement announcements, two further federal regulations, and one national anti-doping agency’s note on the infusion rule in the WADA Prohibited List. The service counts were computed from our own directory of 177 listed US clinics with the site’s own servicesMix function, on data read on September 28, 2026, and every count is given against that denominator; the blocks below are computed from the same dataset when the page is built. Drafting used AI tools. A human editor has not yet checked this guide claim by claim against its sources. No clinical reviewer has signed off on this page yet.